Cybin Inc. CYBN announced that the World Intellectual Property Organization (WIPO) published an international patent application covering a range of inhalation delivery methods for psychedelic molecules.
“Our progress to secure IP for unique psychedelic delivery methods strongly aligns and supports our current CYB004 pipeline program of deuterated DMT via inhalation, which is aimed at overcoming some of the known challenges of oral and IV-administered DMT,” explained the company’s CEO, Doug Drysdale.
The Patent Cooperation Treaty published is called “Methods For Delivery Of Psychedelic Medications By Inhalation And Systems For Performing The Methods,” and Cybin expects that it will be a viable tool to protect currently in-development inhaled forms of psychedelic molecules.
Edge Rankings
Price Trend
© 2025 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.
Cannabis is evolving—don’t get left behind!
Curious about what’s next for the industry and how to stay ahead in today’s competitive market?
Join top executives, investors, and industry leaders at the Benzinga Cannabis Capital Conference in Chicago on June 9-10. Dive deep into market-shaping strategies, investment trends, and brand-building insights that will define the future of cannabis.
Secure your spot now before prices go up—this is where the biggest deals and connections happen!